Here are relevant reports on : clinical-next-generation-sequencing-ngs-market
-
Neurodiagnostics Market by Product (Diagnostic & Imaging Systems (MRI, Ultrasound), Clinical Testing (PCR, NGS), Reagents & Consumables), Disease Pathology (Epilepsy, Stroke), End User and Region - Global Forecasts to 2024
The neurodiagnostics market is projected to reach USD 8.4 billion by 2024, at a CAGR of 7.3%. Some of the prominent players in this market includes GE Healthcare (US), Siemens Healthineers (Germany), Philips Healthcare (Netherlands), Hitachi, Ltd. (Japan), Canon, Inc. (Japan), Lifelines Neuro Company, LLC (US), Natus Medical Incorporated (US), Hoffman-La Roche AG (Switzerland), FUJIFILM Holdings Corporation (Japan), Mitsar Co., Ltd. (Russia), Advanced Brain Monitoring (US), Thermo Fisher Scientific, Inc. (US), Bio-Rad Laboratories (US), QIAGEN N.V. (Netherlands), Nihon Kohden Corporation (Japan), ANT Neuro (Netherlands), Fonar Corporation (US), Fujirebio (Japan), DRG Instruments GmbH (Germany), Tecan Trading AG (Switzerland), Motion Lab Systems, Inc. (US), Rigaku Corporation (Japan), Neusoft Medical Systems Co., Ltd. (US), ELMIKO MEDICAL Sp. Z o.o. (Poland) and Ridge Diagnostics (US).
- Published: December 2019
- Price: $ 4950
- TOC Available:
-
Life Science Instrumentation Market by Technology (Spectroscopy, Chromatography, Immunoassay, NGS, PCR, Microscopy), Application (Diagnostic, Clinical), End User (Pharma, Agriculture & Food Industry, Hospital, Diagnostic Lab) - Global Forecasts to 2031
The global Life Science Instrumentation market, valued at US$59.9 billion in 2024, stood at US$63.4 billion in 2025 and is projected to advance at a resilient CAGR of 6.5% from 2024 to 2030, culminating in a forecasted valuation of US$92.5 billion by the end of the period. The main drivers of the life science instrumentation market include increasing demand for advanced analytical technologies in drug discovery, genomics, and proteomics research, along with rising investments in pharmaceutical and biotechnology R&D.
- Published: November 2025
- Price: $ 4950
- TOC Available:
-
COVID 19 Impact on IVD (In Vitro Diagnostics) Market by Technology (PCR, NGS, ELISA, Rapid Test, Hematology, Hemostasis, Clinical Chemistry, Microbiology Testing, Urinalysis), End-user and Region - Global Forecast to 2025
The COVID 19 Impact on IVD (In Vitro Diagnostics) Market is expected to grow from USD 61.7 billion in 2020 to USD 77.9 billion by 2025, at a CAGR of 4.8% during the forecast period. As of 2019, some of the prominent players in the in-vitro diagnostics market are Roche Diagnostics (Switzerland), Abbott Laboratories (US), Thermo Fisher Scientific (US), Becton, Dickinson and Company (US), Bio-Rad Laboratories (US), Biomerieux (France), and QIAGEN (Germany), among others.
- Published: May 2020
- Price: $ 4950
- TOC Available:
-
Whole Exome Sequencing Market by Product [Systems, Kits (Library Preparation, Target Enrichment)], Services (Sequencing), Technology (Sequencing by Synthesis), & by Application (Cancer, Monogenic disorders) - Global Forecast to 2018
This global whole exome sequencing market was valued at $326.6 million in 2013 and is expected to grow at a CAGR of 22.0% from 2013 to 2018, to reach $884.1 million by 2018. The market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). North America is expected to maintain its leadership in the market in the coming years. Growth in the North American market is likely to be driven by factors such as the increasing use of exome sequencing in rare disease research, increased government funding, and large number of sequencing-related conferences and annual meetings hosted by the U.S.
- Published: August 2014
- Price: $ 4950
- TOC Available:
-
miRNA Sequencing and Assay Market by Product (Library Preparation, Consumables), Technology (Sequencing By Synthesis, Nanopore, Ion Semiconductor Sequencing), End User (Research Institute, Academia, CRO), Region - Global Forecast To 2024
The miRNA sequencing and assays market is projected to reach USD 343 million by 2024, at a CAGR of 11.2%. Growth in this market is driven by factors such as the advantages of miRNA sequencing over other technologies, increasing research funding for genomics, and the decreasing cost of sequencing.Illumina (US), Thermo Fisher Scientific (US), QIAGEN (Germany), Takara Bio (Japan), NEB (UK), and 5 others.
- Published: March 2019
- Price: $ 4950
- TOC Available:
-
Immune Repertoire Sequencing Market by Product (Instrument, Software, Assay Kit & Reagent (TCR, BCR Kit)), Technology (Sequencing, Bioinformatics), Service (Data Analysis), Application (Research, Drug Discovery & Development) - Global Forecast to 2030
Global immune repertoire sequencing market valued at $344.2M in 2024, reached $354.6M in 2025, and is projected to grow at a robust 9.6% CAGR, hitting $560.5M by 2030. The growth of the Asia Pacific IRS market is primarily due to growing R&D investments and the increasing presence of major industry stakeholders in the region.
- Published: April 2025
- Price: $ 4950
- TOC Available:
-
Single-molecule Real-time (SMRT) Sequencing Market by Offering (Products, Services), Workflow (Sequencing, Data Analysis), Application (Drug Discovery, Diagnostic, Agriculture), End User (Academia, Pharma, Biotech) - Forecast to 2030
The Single-molecule Real-time (SMRT) Sequencing Market, valued at US$2.83 billion in 2024, stood at US$2.92 billion in 2025 and is projected to advance at a resilient CAGR of 12.8% from 2025 to 2030, culminating in a forecasted valuation of US$5.32 billion by the end of the period. This market is expanding as long-read sequencing is used more often in rare disease diagnostics, cancer genomics, and broader precision medicine programs.
- Published: December 2025
- Price: $ 4950
- TOC Available:
-
Single Cell Sequencing Market by Product (Reagents & Kits, Platforms, Software), Workflow (Presequencing), Service (Sample Preparation, Bioinformatics), Sequencing (scRNA, scDNA), Application (Research, Diagnostic), End User - Global Forecast to 2030
The global Single Cell Sequencing market, valued at US$1.89 billion in 2024, stood at US$1.95 billion in 2025 and is projected to advance at a resilient CAGR of 12.2% from 2025 to 2030, culminating in a forecasted valuation of US$3.46 billion by the end of the period. This growth is driven by advancements in single-cell workflow, including more efficient cell isolation methods, improved library preparation kits, and high-throughput, cost-effective sequencing platforms.
- Published: July 2025
- Price: $ 4950
- TOC Available:
-
Metagenomic Sequencing Market by Product & Services (Reagent, Consumables, Instrument), Workflow (Sample Preparation, Sequencing), Technology (16S rRNA, Shotgun, Whole-genome), Application (Drug Discovery, Diagnostic, Industrial) - Global Forecast to 2028
The global metagenomic sequencing market, valued at US$1.8 billion in 2022, stood at US$2.0 billion in 2023 and is projected to advance at a resilient CAGR of 17.5% from 2023 to 2028, culminating in a forecasted valuation of US$4.5billion by the end of the period. NGS platforms have undergone continuous technological innovations over the last several years.
- Published: July 2023
- Price: $ 4950
- TOC Available:
-
Home Healthcare Software - Product & Service Market - Application (Clinical, Non - Clinical), Usage (Laptop, Smartphone), Product (Agency, Clinical Management System, Telehealth, Hospice), Delivery (Web - Based, On - Premises, Cloud), End User - Global Forecast to 2018
The global home healthcare software and services market is estimated to reach $6.4 billion by 2018, at a CAGR of 13.4% between 2013 and 2018. The market will be driven by skyrocketing healthcare cost, spiralling aging population that increases the incidences of chronic disorders, hospital readmission reduction program by U.S., shortage of nursing and doctors staff, OASIS documentation, and favorable government initiatives.
- Published: May 2014
- Price: $ 4950
- TOC Available:
Records 21 to 30 of 50
